InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price on the stock.

InspireMD Stock Performance

Shares of NSPR stock opened at $2.80 on Tuesday. The stock has a market cap of $83.13 million, a P/E ratio of -3.73 and a beta of 0.88. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.80. The company has a 50 day simple moving average of $2.86 and a two-hundred day simple moving average of $2.76.

Hedge Funds Weigh In On InspireMD

Institutional investors have recently bought and sold shares of the stock. Parkman Healthcare Partners LLC purchased a new stake in shares of InspireMD during the 3rd quarter worth approximately $279,000. Affiance Financial LLC boosted its position in shares of InspireMD by 2.9% during the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock valued at $497,000 after buying an additional 5,376 shares during the period. Legato Capital Management LLC purchased a new position in InspireMD during the 4th quarter valued at $47,000. Essex Investment Management Co. LLC purchased a new stake in shares of InspireMD during the fourth quarter valued at $191,000. Finally, Renaissance Technologies LLC bought a new stake in InspireMD during the 4th quarter valued at about $27,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.